Clinical Trial Update: Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and safety/pharmacokinetic study of SAR103168 in patients with refractory/relapsed acute myeloid leukemia and high-risk myelodysplastic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• SAR103168

Snippet

Sponsor: Sanofi | Conditions: Acute Myelogenous Leukemia | Phase 1 | Status: COMPLETED